NovaBay Pharmaceuticals Inc
5980 Horton Street
About NovaBay Pharmaceuticals IncNovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.
NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.
365 articles with NovaBay Pharmaceuticals Inc
Self-diagnostic device designed to assist Avenova customers with management of common lid and lash problems
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2021 and provides a business update.
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three months ended March 31, 2021 after market close on Thursday, May 6, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.
NovaBay Pharmaceuticals’ Avenova® Warm Eye Compress for the Relief of Symptoms Associated with Dry Eye is Now Available on Amazon.com and Avenova.com
NovaBay® Pharmaceuticals, Inc., a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on Amazon.com and on Avenova.com.
Avenova ® unit sales set record for second consecutive quarter Net product revenue increased 51% for 2020 Exited 2020 with $12.0 million in cash and equivalents Avenova access expanded to CVS stores and CVS online
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and 12 months ended December 31, 2020 after market close on Thursday, March 25, 2021 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.
NovaBay Pharmaceuticals to Participate in Virtual 33 rd Annual Roth Conference
NovaBay Pharmaceuticals enters 2021 focused on growing sales of our high-quality, differentiated consumer products: Avenova®, the premier antimicrobial lid and lash spray, and CelleRx® Clinical Reset, a breakthrough product that marked our entry into a new beauty category late last year.
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces its proprietary hypochlorous acid solution has received U.S. Environmental Protection Agency (EPA) approval for a kill claim against SARS-CoV-2, the virus that causes COVID-19
NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement with Paragon Care Group Australia Pty Ltd for the exclusive distribution of Avenova in Australia.
NovaBay Pharmaceuticals, Inc. announces the consumer launch of Clinical Reset, an FDA-cleared skincare product proven to help clean and reduce the buildup of bacteria on facial skin.
Revenue increased 34% versus prior year Avenova ® unit sales set quarterly record Exited Q3 with $13.4 million in cash and equivalents Regained compliance with NYSE American continued-listing standards Launches CelleRx ® Clinical Reset™ into beauty market Conference call begins at 4:30 p.m. Eastern time today EMERYVILLE, Calif.--( BUSINESS WIRE )-- NovaBay ® Pharmaceuticals, Inc . (NYSE American:
NovaBay® Pharmaceuticals, Inc. announces it will report financial results for the three and nine months ended September 30, 2020 after market close on Thursday, November 12, 2020 and will hold an investment community conference call that day at 4:30 p.m. Eastern time.
NovaBay® Pharmaceuticals, Inc. announces it believes that it has regained full compliance with the NYSE American’s continued listing standards, subject to NYSE American’s formal confirmation that the Company has regained compliance after the Company files its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020.
NovaBay Pharmaceuticals Expands Avenova® Consumer Marketing through Affiliate Programs and Enhanced Lifestyle Public Relations
NovaBay® Pharmaceuticals, Inc. announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobial lid and lash spray and promote online sales.
NovaBay® Pharmaceuticals, Inc. announces the availability of “subscribe & save” for repeat orders of Avenova® antimicrobial lid & lash solution on Avenova.com and Amazon.com.
NovaBay® Pharmaceuticals, Inc. announces the appointment of President and CEO Justin Hall to the Company’s board of directors, effective August 21, 2020.
Walmart.com joins Amazon.com and Avenova.com in offering Avenova, the only facial spray confirmed through independent laboratory testing to kill the SARS-CoV-2 virus
NovaBay® Pharmaceuticals, Inc. announces it will report financial results for the three and six months ended June 30, 2020 after market close on Thursday, August 6, 2020 and will hold an investment community conference call that day at 4:30 p.m.
NovaBay Pharmaceuticals Announces Laboratory Results Confirm Avenova Kills SARS-CoV-2 (COVID-19 Virus)
NovaBay® Pharmaceuticals, Inc. announces testing results from an independent third-party laboratory confirming that Avenova®, NovaBay’s proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.